Regeneron Pharmaceuticals
Alirocumab
Hypercholesterolemia
Countdown
175days
Phase 2 readout · Dec 29, 2026
What's at stake
Phase 2 trial results for Alirocumab in Hypercholesterolemia are due Dec 29, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07477704: Phase 2 trial, sponsor Regeneron Pharmaceuticals, drug Alirocumab. Primary completion date 2026-12-29 (estimated).”